# US 2002/0058685 A1 · Hydantoin derivative compounds, pharmace utical compositions, and methods of using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0058685 A1
- Document ID: US20020058685A1
- Status: Published application
- Kind: A1
- Application number: 09/741,437
- Filed: 2000-12-21
- Published: 2002-05-16
- Earliest claimed: 1999-12-21
- Assignees: GPI NIL Holdindgs, Inc.
- Inventors: Gregory S. Hamilton
- Web page: https://patentgrep.com/patent/US20020058685A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 17/14: for baldness or alopecia
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates generally to novel hydantoin derivative compounds, pharmaceutical compositions containing such compounds, and methods for their use in preventing and/or treating neurological disorders, including physically damaged nerves and neurodegenerative diseases; for treating alopecia and promoting hair growth; for treating vision disorders and/or improving vision; for treating memory impairment and/or enhancing memory performance; and for treating sensorineural hearing loss by administering such compounds.

## Claims

### Claim 1

A compound of the formula:
14
where
each X independently is O, S, or NR2;
R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
D is a direct bond or a C1-C8 alkyl or alkenyl;
R is selected from the group consisting of hydrogen, phenyl, biphenyl, cyclopropyl, cyclobutyl, cyclopentyl, cycloheptyl, cyclooctyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, isoindolyl, indolinyl, benzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, tetrahydrofuranyl, tetrahydropyranyl, pyridyl, pyrrolyl, pyrrolidinyl, pyridinyl, pyrimidinyl, purinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, quinolizinyl, furyl, benzofuranyl, thiophenyl, imidazolyl, oxazolyl, benzoxazolyl, benzoxazinyl, thiazolyl, isoxazolyl, isotriazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, trithianyl, indolizinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, benzopyranyl, thienyl, tetrahydroisoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, phenazinyl, phenothiazinyl, phenoxazinyl, and adamantyl;
wherein R may be optionally substituted with one substituent which is selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
or a pharmaceutically acceptable salt, ester, or solvate thereof;
wherein when R is hydrogen, D is a C5-C7 alkyl or C5-C8 alkenyl;
wherein when R is phenyl and D is a bond, R must be substituted with phenyl, hydroxyl, trifluoromethyl, C2-C6 straight or branched chain alkyl or alkenyl, C3-C4 alkoxy or C2-C4 alkenyloxy, phenoxy, or benzyloxy;
wherein when R is 4-trifluoromethylphenyl, both X substituents must be O.

### Claim 2 (depends on 1)

The compound according to claim 1 that is selected from the group consisting of:
(7aS)-2-(1-Naphthyl)perhydropyrrolo[1,2-c]imidazole-1,3-dione,
(7aS)-2-(2′-Phenyl)phenylperhydropyrrolo[1,2-c]imidazole-1,3-dione,
(7aS)-2-(4-(Trifluoromethyl)phenyl)perhydropyrrolo [1,2-c]imidazole-1,3-dione,
2-benzyl-3-thioxo-2,5,6,7,7a-pentahydro-2-azapyrrolizin-1-one,
2-hexyl-2,5,6,7,7a-pentahydro-2-azapyrrolizine-1,3-dione,
2-(2-ethyl)phenyl-2,5,6,7,7a-pentahydro-2-azapyrrolizin-1,3-dione,
2-(3-phenylpropyl)-3-thioxo-2,5,6,7,7a-pentahydro-2-azapyrrolizin-l-one, and
2-(2-phenylethyl)-3-thioxo-2,5,6,7,7a-pentahydro-2-azapyrrolizin-1-one.

### Claim 3

A pharmaceutical composition comprising an effective amount of a compound and a pharmaceutically acceptable carrier, wherein the compound is of the formula:
15
where
each X independently is O, S, or NR2;
R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
D is a direct bond or C1-C8 alkyl or alkenyl;
R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring;
wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
or a pharmaceutically acceptable salt, ester, or solvate thereof.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, further comprising an additional neurotrophic factor.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the additional neurotrophic factor is selected from the group consisting of neurotrophic growth factor, brain derived growth factor, glial derived growth factor, cilial neurotrophic factor, insulin growth factor and active truncated derivatives thereof, acidic fibroblast growth factor, basic fibroblast growth factor, platelet-derived growth factors, neurotropin-3, and neurotropin-⅘.

### Claim 6

A method of treating a neurological disorder in an animal, comprising:
administering to the animal an effective amount of a compound to stimulate growth of damaged peripheral nerves or to promote neuronal regeneration, wherein the compound is of the formula:
16
where
each X independently is O, S, or NR2;
R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
D is a direct bond or C1-C8 alkyl or alkenyl;
R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring;
wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino; or a pharmaceutically acceptable salt, ester, or solvate thereof.

### Claim 7 (depends on 6)

The method of claim 6, wherein the neurological disorder is selected from the group consisting of peripheral neuropathies caused by physical injury or disease state, physical damage to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorders relating to neurodegeneration.

### Claim 8 (depends on 6)

The method of claim 6, wherein the neurological disorder is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis, and Huntington's Disease.

### Claim 9 (depends on 6)

The method of claim 6, wherein the neurological disorder is Alzheimer's Disease.

### Claim 10 (depends on 6)

The method of claim 6, wherein the neurological disorder is Parkinson's Disease.

### Claim 11 (depends on 6)

The method of claim 6, wherein the neurological disorder is amyotrophic lateral sclerosis.

### Claim 12 (depends on 6)

The method of claim 6, wherein the neurological disorder is Huntington's Disease.

### Claim 13 (depends on 6)

The method of claim 6, wherein the compound is non-immunosuppressive.

### Claim 14 (depends on 6)

The method of claim 6, further comprising administrating an additional neurotrophic factor.

### Claim 15 (depends on 14)

The method of claim 14, wherein the additional neurotrophic factor is selected from the group consisting of neurotrophic growth factor, brain derived growth factor, glial derived growth factor, cilial neurotrophic factor, insulin growth factor and active truncated derivatives thereof, acidic fibroblast growth factor, basic fibroblast growth factor, platelet-derived growth factors, neurotropin-3, and neurotropin-⅘.

### Claim 16

A method of stimulating growth of damaged peripheral nerves, comprising:
administering to damaged peripheral nerves an effective amount of a compound to stimulate or promote growth of the damaged peripheral nerves, wherein the compound is of the formula:
17
where
each X independently is O, S, or NR2;
R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
D is a direct bond or C1-C8 alkyl or alkenyl;
R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring;
wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
or a pharmaceutically acceptable salt, ester, or solvate thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the compound is non-immunosuppressive.

### Claim 18 (depends on 16)

The method of claim 16, further comprising administrating an additional neurotrophic factor.

### Claim 19 (depends on 18)

The method of claim 18, wherein the additional neurotrophic factor is selected from the group consisting of neurotrophic growth factor, brain derived growth factor, glial derived growth factor, cilial neurotrophic factor, insulin growth factor and active truncated derivatives thereof, acidic fibroblast growth factor, basic fibroblast growth factor, platelet-derived growth factors, neurotropin-3, and neurotropin-⅘.

### Claim 20

A method for promoting neuronal regeneration and growth in animals, comprising:
administering to an animal an effective amount of a compound to promote neuronal regeneration, wherein the compound is of the formula:
18
where
each X independently is O, S, or NR2;
R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
D is a direct bond or C1-C8 alkyl or alkenyl;
R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring;
wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
or a pharmaceutically acceptable salt, ester, or solvate thereof.

### Claim 21 (depends on 20)

The method of claim 20, wherein the compound is non-immunosuppressive.

### Claim 22 (depends on 20)

The method of claim 20, further comprising administrating an additional neurotrophic factor.

### Claim 23 (depends on 22)

The method of claim 22, wherein the additional neurotrophic factor is selected from the group consisting of neurotrophic growth factor, brain derived growth factor, glial derived growth factor, cilial neurotrophic factor, insulin growth factor and active truncated derivatives thereof, acidic fibroblast growth factor, basic fibroblast growth factor, platelet-derived growth factors, neurotropin-3, and neurotropin-⅘.

### Claim 24

A method for preventing neurodegeneration in an animal, comprising:
administering to an animal an effective amount of a compound to prevent neurodegeneration, wherein the compound is of the formula:
19
where
each X independently is O, S, or NR2;
R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
D is a direct bond or C1-C8 alkyl or alkenyl;
R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring;
wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
or a pharmaceutically acceptable salt, ester, or solvate thereof.

### Claim 25 (depends on 24)

The method of claim 24, wherein the neurodegeneration is Alzheimer's Disease.

### Claim 26 (depends on 24)

The method of claim 24, wherein the neurodegeneration is Parkinson's Disease.

### Claim 27 (depends on 24)

The method of claim 24, wherein the neurodegeneration is amyotrophic lateral sclerosis.

### Claim 28 (depends on 24)

The method of claim 24, wherein the neurodegeneration is Huntington's Disease.

### Claim 29 (depends on 24)

The method of claim 24, wherein the compound is non-immunosuppressive.

### Claim 30 (depends on 24)

The method of claim 24, further comprising administrating an additional neurotrophic factor.

### Claim 31 (depends on 30)

The method of claim 30, wherein the additional neurotrophic factor is selected from the group consisting of neurotrophic growth factor, brain derived growth factor, glial derived growth factor, cilial neurotrophic factor, insulin growth factor and active truncated derivatives thereof, acidic fibroblast growth factor, basic fibroblast growth factor, platelet-derived growth factors, neurotropin-3, and neurotropin-⅘.

### Claim 32

A compound of the formula:
20
where
each X independently is O, S, or NR2;
R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
D is a direct bond or a C1-C8 alkyl or alkenyl;
R is selected from the group consisting of hydrogen, phenyl, biphenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 1,2,3,4-tetrahydronaphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, indolyl, isoindolyl, indolinyl, benzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, tetrahydrofuranyl, tetrahydropyranyl, pyridyl, pyrrolyl, pyrrolidinyl, pyridinyl, pyrimidinyl, purinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, quinolizinyl, furyl, thiophenyl, imidazolyl, oxazolyl, benzopyranyl, thiazolyl, isotriazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, trithianyl, indolizinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, thienyl, tetrahydroisoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, and adamantyl;
wherein R may be optionally substituted with one substituent which is selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
or a pharmaceutically acceptable salt, ester, or solvate thereof;
wherein when R is hydrogen, D is a C5-C8 alkyl or alkenyl;
wherein when R is phenyl and D is a bond, R must be substituted with C2-C3 or C1-C6 straight or branched chain alkyl or alkenyl, C3-C4 alkoxy or C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, or amino.

### Claim 33 (depends on 32)

The compound according to claim 32 that is selected from the group consisting of:
2-Benzyl-2,5,6,7,8,8a-hexahydro-2-azaindolizine-1,3-dione,
2-benzyl-3-thioxo-2,5,6,7,8,8a-hexahydro-2-azaindolizin-1-one,
2-(2-phenylethyl)-3-thioxo-2,5,6,7,8,8a-hexahydro-
2-azaindolizin-1-one, 2-Heptyl-2,5,6,7,8,8a-hexahydro-2-azaindolizine-1,3-dione,
2-Octyl-2,5,6,7,8,8a-hexahydro-2-azaindolizine-1,3-dione,
2-(3-phenylpropyl)-3-thioxo-2,5,6,7,8,8a-hexahydro-2-azaindolizin-1-one,
2-hexyl-2,5,6,7,8,8a-hexahydro-2-azaindolizine-1,3-dione, and
2-Cyclohexyl-2,5,6,7,8,8a-hexahydro-2-azaindolizine-1,3-dione.

### Claim 34

A pharmaceutical composition comprising an effective amount of a compound and a pharmaceutically acceptable carrier, wherein the compound is of the formula:
21
where
each X independently is O, S, or NR2;
R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
D is a direct bond or C1-C8 alkyl or alkenyl;
R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring;
wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
or a pharmaceutically acceptable salt, ester, or solvate thereof.

### Claim 35 (depends on 34)

The pharmaceutical composition of claim 34, further comprising an additional neurotrophic factor.

### Claim 36 (depends on 35)

The pharmaceutical composition of claim 35, wherein the additional neurotrophic factor is selected from the group consisting of neurotrophic growth factor, brain derived growth factor, glial derived growth factor, cilial neurotrophic factor, insulin growth factor and active truncated derivatives thereof, acidic fibroblast growth factor, basic fibroblast growth factor, platelet-derived growth factors, neurotropin-3, and neurotropin-⅘.

### Claim 37

A method of treating a neurological disorder in an animal, comprising:
administering to the animal an effective amount of a compound to stimulate growth of damaged peripheral nerves or to promote neuronal regeneration, wherein the compound is of the formula:
22
where
each X independently is O, S, or NR2;
R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
D is a direct bond or C1-C8 alkyl or alkenyl;
R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring;
wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
or a pharmaceutically acceptable salt, ester, or solvate thereof.

### Claim 38 (depends on 37)

The method of claim 37, wherein the neurological disorder is selected from the group consisting of peripheral neuropathies caused by physical injury or disease state, physical damage to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorders relating to neurodegeneration.

### Claim 39 (depends on 37)

The method of claim 37, wherein the neurological disorder is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis, and Huntington's Disease.

### Claim 40 (depends on 37)

The method of claim 37, wherein the neurological disorder is Alzheimer's Disease.

### Claim 41 (depends on 37)

The method of claim 37, wherein the neurological disorder is Parkinson's Disease.

### Claim 42 (depends on 37)

The method of claim 37, wherein the neurological disorder is amyotrophic lateral sclerosis.

### Claim 43 (depends on 37)

The method of claim 37, wherein the neurological disorder is Huntington's Disease.

### Claim 44 (depends on 37)

The method of claim 37, wherein the compound is non-immunosuppressive.

### Claim 45 (depends on 37)

The method of claim 37, further comprising administrating an additional neurotrophic factor.

### Claim 46 (depends on 45)

The method of claim 45, wherein the additional neurotrophic factor is selected from the group consisting of neurotrophic growth factor, brain derived growth factor, glial derived growth factor, cilial neurotrophic factor, insulin growth factor and active truncated derivatives thereof, acidic fibroblast growth factor, basic fibroblast growth factor, platelet-derived growth factors, neurotropin-3, and neurotropin-⅘.

### Claim 47

A method of stimulating growth of damaged peripheral nerves, comprising:
administering to damaged peripheral nerves an effective amount of a compound to stimulate or promote growth of the damaged peripheral nerves, wherein the compound is of the formula:
23
where
each X independently is O, S, or NR2;
R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
D is a direct bond or C1-C8 alkyl or alkenyl;
R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring;
wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
or a pharmaceutically acceptable salt, ester, or solvate thereof.

### Claim 48 (depends on 47)

The method of claim 47, wherein the compound is non-immunosuppressive.

### Claim 49 (depends on 47)

The method of claim 47, further comprising administrating an additional neurotrophic factor.

### Claim 50 (depends on 49)

The method of claim 49, wherein the additional neurotrophic factor is selected from the group consisting of neurotrophic growth factor, brain derived growth factor, glial derived growth factor, cilial neurotrophic factor, insulin growth factor and active truncated derivatives thereof, acidic fibroblast growth factor, basic fibroblast growth factor, platelet-derived growth factors, neurotropin-3, and neurotropin-⅘.

### Claim 51

A method for promoting neuronal regeneration and growth in animals, comprising:
administering to an animal an effective amount of a compound to promote neuronal regeneration, wherein the compound is of the formula:
24
where
each X independently is O, S, or NR2;
R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
D is a direct bond or C1-C8 alkyl or alkenyl;
R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring;
wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
or a pharmaceutically acceptable salt, ester, or solvate thereof.

### Claim 52 (depends on 51)

The method of claim 51, wherein the compound is non-immunosuppressive.

### Claim 53 (depends on 51)

The method of claim 51, further comprising administrating an additional neurotrophic factor.

### Claim 54 (depends on 53)

The method of claim 53, wherein the additional neurotrophic factor is selected from the group consisting of neurotrophic growth factor, brain derived growth factor, glial derived growth factor, cilial neurotrophic factor, insulin growth factor and active truncated derivatives thereof, acidic fibroblast growth factor, basic fibroblast growth factor, platelet-derived growth factors, neurotropin-3, and neurotropin-⅘.

### Claim 55

A method for preventing neurodegeneration in an animal, comprising:
administering to an animal an effective amount of a compound to prevent neurodegeneration, wherein the compound is of the formula:
25
where
each X independently is O, S, or NR2;
R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
D is a direct bond or C1-C8, alkyl or alkenyl;
R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring;
wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
or a pharmaceutically acceptable salt, ester, or solvate thereof.

### Claim 56 (depends on 55)

The method of claim 55, wherein the neurodegeneration is Alzheimer's Disease.

### Claim 57 (depends on 55)

The method of claim 55, wherein the neurodegeneration is Parkinson's Disease.

### Claim 58 (depends on 55)

The method of claim 55, wherein the neurodegeneration is amyotrophic lateral sclerosis.

### Claim 59 (depends on 55)

The method of claim 55, wherein the neurodegeneration is Huntington's Disease.

### Claim 60 (depends on 55)

The method of claim 55, wherein the compound is non-immunosuppressive.

### Claim 61 (depends on 55)

The method of claim 55, further comprising administrating an additional neurotrophic factor.

### Claim 62 (depends on 61)

The method of claim 61, wherein the additional neurotrophic factor is selected from the group consisting of neurotrophic growth factor, brain derived growth factor, glial derived growth factor, cilial neurotrophic factor, insulin growth factor and active truncated derivatives thereof, acidic fibroblast growth factor, basic fibroblast growth factor, platelet-derived growth factors, neurotropin-3, and neurotropin-⅘.
